Head-to-head evidence
Pegmolesatide (HS-20039) vs RD01 (PEG-EPO)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
Pegmolesatide (HS-20039)
Marketed by Hansoh Pharmaceutical Group
NCT03902691 · Phase 3 · completed
This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.
Next expected readout: December 2026 · NCT07136792 (registry estimate)
RD01 (PEG-EPO)
Developed by Shenzhen Sciprogen Bio-pharmaceutical
NCT04231292 · Phase 2 · status unknown
This is a randomized, controlled trial (active and placebo comparator arms) using hemoglobin concentration, the disease-defining measure for anemia, as its primary endpoint, but only participants were masked (not investigators or assessors), and no results have yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pegmolesatide (HS-20039)'s landscape · RD01 (PEG-EPO)'s landscape